

17 Mar 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer's plans for Adcetris in DLBCL; Lilly's donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS's CDTO Greg Meyers.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 March 2024, including: [*Galderma S.A.*](#) prepares to take on Dupixent; [*Pfizer Inc.*](#)'s plans for Adcetris in DLBCL; [*Eli Lilly and Company*](#)'s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with [*Bristol Myers Squibb Company*](#)'s CDTO Greg Meyers.

This and all our other podcasts are available on the *Citeline* channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent*](#)" - Scrip, 11 Mar, 2024.)

(Also see "[*In Competitive DLBCL Setting, Pfizer Goes Old School With Adcetris*](#)" - Scrip, 12 Mar, 2024.)

(Also see "[*Three Strikes, But Not Out Yet, Lilly's Donanemab Approval Delayed Again*](#)" - Scrip, 8 Mar, 2024.)

(Also see "[*A Visual Trip Through The Psychedelic Pipeline*](#)" - Scrip, 8 Mar, 2024.)

(Also see "[*BMS CDTO Meyers On Gen AI Use Cases, Long-Range Planning Models*](#)" - Scrip, 8 Mar, 2024.)

[Click here to explore this interactive content online](#) ✨